Moderna (MRNA) Gross Margin (2020 - 2026)

Moderna (MRNA) has 7 years of Gross Margin data on file, last reported at 145.5% in Q1 2026.

• On a quarterly basis, Gross Margin fell 16217.0% year-over-year to 145.5% in Q1 2026; TTM through Mar 2026 was 22.11%, a 3200.0% decrease from a year earlier, with the FY2025 full-year figure at 55.35%, up 59.0% from the prior year.
• Gross Margin for Q1 2026 stood at 145.5%, down from 33.33% in the prior quarter.
• Over the last five years, Gross Margin for MRNA reached as high as 92.13% in Q4 2022 and fell as low as 145.5% in Q1 2026.
• Historically, Gross Margin has averaged 29.07% across 5 years, with a median of 52.28% in 2024.
• Across the five-year window, Gross Margin slumped 18342 bps in 2023 and surged 16478 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 92.13% in 2022, then decreased by 27 bps to 66.95% in 2023, then tumbled by 65 bps to 23.5% in 2024, then jumped by 42 bps to 33.33% in 2025, then slumped by 537 bps to 145.5% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 145.5% in Q1 2026, 33.33% in Q4 2025, and 79.63% in Q3 2025.